Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia Oakes

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Hospital Medicine|April 16, 2017
What Are the Chances?Stefanie Deeds, Patricia Oakes, Somnath Mookherjee, et al.
Neurocritical Care|June 15, 2007
An unsuccessful trial of immunomodulatory therapy in delayed posthypoxic demyelinationSandeep Khot, Melanie Walker, J Matthew Lacy, et al.
Cancer Chemotherapy and Pharmacology|January 23, 2014
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumorsEdward Sausville, Patricia Lorusso, Michael Carducci, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Hospital Medicine|April 16, 2017
What Are the Chances?Stefanie Deeds, Patricia Oakes, Somnath Mookherjee, et al.
Neurocritical Care|June 15, 2007
An unsuccessful trial of immunomodulatory therapy in delayed posthypoxic demyelinationSandeep Khot, Melanie Walker, J Matthew Lacy, et al.
Cancer Chemotherapy and Pharmacology|January 23, 2014
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumorsEdward Sausville, Patricia Lorusso, Michael Carducci, et al.
Pageof 1